ArticleMultiple sclerosis journal - experimental, translational and clinical
Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.The European journal of neuroscience · 2022Pooled it
- Neurofilaments in progressive multiple sclerosis: a systematic review.Journal of neurology · 2021Pooled it
- Combined plasma and imaging biomarkers as predictors of neurological outcome in cervical traumatic spinal cord injury.BMC neurology · 2026Article
- Effect of Ibudilast vs Placebo on GFAP and Contactin levels in a phase 2 clinical trial in progressive multiple sclerosis.Neurology open access · 2025Article
- Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS.Scientific reports · 2024Article
- CNTN1 in the Nucleus Accumbens is Involved in Methamphetamine-Induced Conditioned Place Preference in Mice.Neurotoxicity research · 2023Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Biomarkers in autoimmune diseases of the central nervous system.Frontiers in immunology · 2023Review
- Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study.Brain communications · 2023Article
- Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Structural insights into the contactin 1 - neurofascin 155 adhesion complex.Nature communications · 2022Article
- Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.Biomedicines · 2022Review
- Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Implication of Contactins in Demyelinating Pathologies.Life (Basel, Switzerland) · 2021Review
- Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS.Acta neuropathologica communications · 2020Article
- Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.Biomolecules · 2020Article
- Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial.BMC neurology · 2020Article
- The Role of Contactin 1 in Cancers: What We Know So Far.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContactin-1 and contactin-2 are important for the maintenance of axonal integrity.
objectiveTo investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration.
methodsCerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing-remitting multiple sclerosis (
resultsContactin-1 and contactin-2 levels were up to 1.4-fold reduced in relapsing-remitting multiple sclerosis (contactin-1:
conclusionCerebrospinal fluid contactin-1 and contactin-2 reveal axonal dysfunction in various stages of multiple sclerosis and their inclusion to the biomarker panel may provide better insight into the extent of axonal damage/dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.